Response to Comments: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

This A59519 document is a response-to-comments notice and does not state medical coverage indications, limitations, documentation requirements, or frequency limits for molecular biomarker testing in rheumatoid arthritis. It references Local Coverage Determinations L39427 (comment period 09/01/2022–10/15/2022) and L39424 (notice 08/31/2023, effective 10/15/2023); review of those LCDs is required to extract specific coverage criteria.

"This document is a response-to-comments notice and does not contain clinical coverage criteria; it references LCD L39427 (comment period 09/01/2022–10/15/2022) and LCD L39424 (notice begins 08/31/2..."

Sign up to see full coverage criteria, indications, and limitations.